La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Adaptive Biotechnologies Gestion

Gestion contrôle des critères 2/4

Nous ne disposons actuellement pas d’informations suffisantes sur le PDG.

Informations clés

Chad Robins

Directeur général

US$8.9m

Rémunération totale

Pourcentage du salaire du PDG	7.4%
Durée du mandat du directeur général	15yrs
Propriété du PDG	1.2%
Durée moyenne d'occupation des postes de direction	5.5yrs
Durée moyenne du mandat des membres du conseil d'administration	8.7yrs

Mises à jour récentes de la gestion

Recent updates

Analyse de la rémunération des PDG

Comment la rémunération de Chad Robins a-t-elle évolué par rapport aux bénéfices de Adaptive Biotechnologies?
Date	Rémunération totale	Salaire	Bénéfices de l'entreprise
Jun 30 2024	n/a	n/a	-US$213m
Mar 31 2024	n/a	n/a	-US$215m
Dec 31 2023	US$9m	US$663k	-US$225m
Sep 30 2023	n/a	n/a	-US$196m
Jun 30 2023	n/a	n/a	-US$191m
Mar 31 2023	n/a	n/a	-US$195m
Dec 31 2022	US$9m	US$658k	-US$200m
Sep 30 2022	n/a	n/a	-US$221m
Jun 30 2022	n/a	n/a	-US$232m
Mar 31 2022	n/a	n/a	-US$229m
Dec 31 2021	US$9m	US$639k	-US$207m
Sep 30 2021	n/a	n/a	-US$190m
Jun 30 2021	n/a	n/a	-US$171m
Mar 31 2021	n/a	n/a	-US$155m
Dec 31 2020	US$7m	US$597k	-US$146m
Sep 30 2020	n/a	n/a	-US$122m
Jun 30 2020	n/a	n/a	-US$99m
Mar 31 2020	n/a	n/a	-US$82m
Dec 31 2019	US$3m	US$493k	-US$70m
Sep 30 2019	n/a	n/a	-US$62m
Jun 30 2019	n/a	n/a	-US$56m
Mar 31 2019	n/a	n/a	-US$53m
Dec 31 2018	US$3m	US$423k	-US$46m

Rémunération vs marché: La rémunération totale de Chad ($USD 8.90M ) est supérieure à la moyenne des entreprises de taille similaire sur le marché German ($USD 1.43M ).

Rémunération et revenus: La rémunération de Chad a augmenté alors que l'entreprise n'est pas rentable.

PDG

Chad Robins (49 yo)

15yrs

Titularisation

US$8,904,267

Compensation

Mr. Chad M. Robins, M.B.A., serves as Independent Director at CM Life Sciences III Inc. since April 07, 2021. He serves as an Independent Director at ARYA Sciences Acquisition Corp II since June 2020. He c...

Équipe de direction

Nom	Position	Titularisation	Compensation	Propriété
Chad Robins	Co-Founder	15yrs	US$8.90m	1.23% $ 8.0m
Julie Rubinstein	President & COO	6.6yrs	US$2.97m	0.32% $ 2.1m
Harlan Robins	Co-Founder & Chief Scientific Officer	15yrs	US$8.61m	0.69% $ 4.5m
Sharon Benzeno	Chief Commercial Officer of Immune Medicine	6.6yrs	US$2.88m	0.22% $ 1.4m
Christopher Carlson	Founder	no data	pas de données	pas de données
Kyle Piskel	VP, CFO & Principal Accounting Officer	2.9yrs	US$1.66m	0.10% $ 678.4k
Karina Calzadilla	Vice President of Investor Relations	no data	pas de données	pas de données
Stacy Taylor	Senior VP	5.5yrs	pas de données	0.095% $ 611.6k
Francis Lo	Chief People Officer	5.4yrs	pas de données	0.17% $ 1.1m
Susan Bobulsky	Chief Commercial Officer of MRD	4.1yrs	pas de données	0.17% $ 1.1m
Mary Lancelotta	Senior Vice President of MRD BioPharma	less than a year	pas de données	pas de données

5.5yrs

Durée moyenne de l'emploi

49.5yo

Âge moyen

Gestion expérimentée: L'équipe de direction de 1HM est chevronnée et expérimentée (ancienneté moyenne 5.4 ans).

Membres du conseil d'administration

Nom	Position	Titularisation	Compensation	Propriété
Chad Robins	Co-Founder	15yrs	US$8.90m	1.23% $ 8.0m
Peter Neupert	Lead Independent Director	10.8yrs	US$355.00k	0.094% $ 605.5k
H. Parker	Member of Corporate Advisory Board	no data	pas de données	pas de données
Michelle Griffin	Independent Director	5.5yrs	US$330.00k	0.035% $ 228.0k
Robert Hershberg	Independent Director	11.6yrs	US$325.00k	0.052% $ 333.4k
Michael Pellini	Independent Director	6.6yrs	US$310.00k	0.037% $ 238.3k
Carol Gallagher	Member of Corporate Advisory Board	no data	pas de données	pas de données
Craig Weissman	Member of Corporate Advisory Board	no data	pas de données	pas de données
Graham Allen	Member of Corporate Advisory Board	no data	pas de données	pas de données
Matthew Kahn	Member of Corporate Advisory Board	no data	pas de données	pas de données
Katey Owen	Independent Director	3.5yrs	US$310.00k	0.038% $ 246.3k

8.7yrs

Durée moyenne de l'emploi

58.5yo

Âge moyen

Conseil d'administration expérimenté: Les membres du conseil d'administration de 1HM sont considérés comme expérimentés (ancienneté moyenne 8.6 ans).

Adaptive Biotechnologies Gestion

Gestion contrôle des critères 2/4

Informations clés

Mises à jour récentes de la gestion

Adaptive Biotechnologies Corporation, Annual General Meeting, Jun 07, 2024

Adaptive Biotechnologies Corporation Announces CFO Changes

Insufficient new directors

Co-Founder recently sold €154k worth of stock

Adaptive Biotechnologies Corporation Announces Executive Changes

Insufficient new directors

Recent updates

Adaptive Announces IVDR Certification for clonoSEQ® in European Union

Second quarter 2024 earnings released: US$0.31 loss per share (vs US$0.33 loss in 2Q 2023)

Adaptive Biotechnologies Corporation to Report Q2, 2024 Results on Aug 01, 2024

First quarter 2024 earnings released: US$0.33 loss per share (vs US$0.40 loss in 1Q 2023)

Adaptive Biotechnologies Corporation, Annual General Meeting, Jun 07, 2024

New minor risk - Shareholder dilution

Adaptive Biotechnologies Corporation to Report Q1, 2024 Results on May 07, 2024

Adaptive Biotechnologies Corporation Announces CFO Changes

Adaptive Biotechnologies Corporation Provides Revenue Guidance for the First Quarter Ended March 31, 2024

Insufficient new directors

Co-Founder recently sold €154k worth of stock

Full year 2023 earnings released: US$1.56 loss per share (vs US$1.41 loss in FY 2022)

Full year 2023 earnings released: US$1.56 loss per share (vs US$1.41 loss in FY 2022)

Adaptive Biotechnologies Corporation to Report Q4, 2023 Results on Feb 14, 2024

Adaptive Biotechnologies Corporation and Collaborators to Present More Than 30 Abstracts Demonstrating the Actionability of ClonoSEQ MRD Testing in Blood Cancer Patient Care and Drug Development at the 65th Annual Meeting

Adaptive Biotechnologies Corporation Updates Revenue Guidance for the Full Year 2023

Third quarter 2023 earnings released: US$0.35 loss per share (vs US$0.32 loss in 3Q 2022)

Adaptive Biotechnologies Corporation to Report Q3, 2023 Results on Nov 09, 2023

Adaptive Biotechnologies Corporation Announces Launch of Epic Integration for ClonosEQ

Adaptive Biotechnologies Corporation Announces Executive Changes

Second quarter 2023 earnings released: US$0.33 loss per share (vs US$0.37 loss in 2Q 2022)

Adaptive Biotechnologies Corporation to Report Q2, 2023 Results on Aug 02, 2023

Adaptive Biotechnologies Corporation to Report Q2, 2023 Results on Aug 02, 2023

Insufficient new directors

New major risk - Share price stability

Adaptive Biotechnologies Corporation Announces Resignation of Leslie Trigg from the Board

Chief Financial Officer recently sold €254k worth of stock

Adaptive Biotechnologies Highlights New Data At ASCO 2023 and EHA 2023 Underscoring the Clonoseq® Assay's Impact as A Standard for Minimal Residual Disease Assessment in Patients with Hematologic Cancer

Adaptive Biotechnologies Corporation Announces FDA Acceptance of Genentech's Investigational New Drug Application for the First Neoantigen-Directed T-Cell Therapy Product in Oncology

Adaptive Biotechnologies Corporation Provides Revenue Guidance for the Full Year 2023

First quarter 2023 earnings released: US$0.40 loss per share (vs US$0.44 loss in 1Q 2022)

President recently sold €182k worth of stock

Adaptive Biotechnologies Corporation Provides Revenue Guidance for Full Year 2023

Full year 2022 earnings released: US$1.41 loss per share (vs US$1.48 loss in FY 2021)

Adaptive Biotechnologies Corporation to Report Q4, 2022 Results on Feb 14, 2023

Adaptive Biotechnologies Announces Launch of clonoSEQ® to Assess Minimal Residual Disease in Patients with Diffuse Large B-Cell Lymphoma Using Circulating Tumor DNA

Third quarter 2022 earnings released: US$0.32 loss per share (vs US$0.40 loss in 3Q 2021)

Adaptive Biotechnologies Corporation Provides Revenue Guidance for the Full Year 2022

Adaptive Biotechnologies Corporation to Report Q3, 2022 Results on Nov 03, 2022

Chief Commercial Officer of MRD recently sold €190k worth of stock

Second quarter 2022 earnings released: US$0.37 loss per share (vs US$0.35 loss in 2Q 2021)

Adaptive Biotechnologies Corporation Reiterates Revenue Guidance for the Full Year 2022

Adaptive Biotechnologies Corporation to Report Q2, 2022 Results on Aug 03, 2022

Adaptive Biotechnologies Launches T-Detect™ Lyme, A New T-Cell Clinical Test for the Detection of Early Lyme Disease

Adaptive Biotechnologies Corporation Includes in Several Abstracts Investigating the Impact of Mrd in Blood Cancers At the American Society of Clinical Oncology

First quarter 2022 earnings released: US$0.44 loss per share (vs US$0.29 loss in 1Q 2021)

Adaptive Biotechnologies Corporation Reiterates Revenue Guidance for the Full Year 2022

Adaptive Biotechnologies Corporation, Annual General Meeting, Jun 10, 2022

Adaptive Biotechnologies Corporation to Report Q1, 2022 Results on May 04, 2022

President recently sold €51k worth of stock

Adaptive Biotechnologies Corporation Announces New Data Demonstrating ImmunoSEQ® Technology Can Identify T-Cell Receptors Associated with Crohn’s Disease

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Adaptive Biotechnologies Corporation Announces CFO Changes

Adaptive Biotechnologies Corporation Announces New Data Demonstrating the Benefit of Serial MRD Testing with the clonoSEQ® Assay in Patients with Blood Cancers at the 63rd ASH Annual Meeting

Adaptive Biotechnologies Corporation Present More than 30 Abstracts on Utility of clonoSEQ® in MRD Testing in Blood Cancer Patients at the 63rd ASH Annual Meeting

Third quarter 2021 earnings released: US$0.40 loss per share (vs US$0.27 loss in 3Q 2020)

Director Kevin Conroy has joined 4th company board

Adaptive Biotechnologies Corporation Provides Earnings Guidance for Full Year 2021

Second quarter 2021 earnings released: US$0.35 loss per share (vs US$0.26 loss in 2Q 2020)

Adaptive Biotechnologies Corporation Announces New Study Published in Nature Provides Further Evidence COVID-19 Vaccine Induced T-Cell Response Targets Known SARS-CoV-2 Variants of Concern

Adaptive Biotechnologies Corporation Provides Financial Guidance for 2021

First quarter 2021 earnings released: US$0.29 loss per share (vs US$0.25 loss in 1Q 2020)

Insider recently sold €128k worth of stock

Adaptive Biotechnologies Corporation Announces Board Changes

Independent Director has left the company

Independent Director has left the company

Adaptive Biotechnologies Announces FDA Emergency Use Authorization for T-Detect™ COVID to Confirm Recent or Prior COVID-19 Infection

New 90-day low: €33.80

Adaptive Biotechnologies Corporation and Genentech, Inc. Collaborate the Development of Cellular Therapy Drugs for Treating Cancer by Targeting Immune Cells to Specific Shared and Personalized Cancer-Related Antigen Targets